After 14 years, Eden Bioscience Corp. is pulling the plug. The Woodinville agricultural science company today said it was liquidating assets and dissolving. The company, which will be delisted from Nasdaq, said it was instituting a plan for an "orderly wind down."

The decision follows the sale of its proprietary harpin protein technology to Plant Health Care in February 2007 for $2.2 million. Eden, which had $5 million in cash and cash equivalents at the end of the last quarter, posted revenue of $166,682 for the first nine months and a net loss of $343,550.

The company noted in the press release:

"Since that sale, the Company's business strategy has been to use any revenue generated by its home and garden business to support the Company's continued operations while it explored whether there may be opportunities to realize potential value from the Company's remaining business assets, primarily its tax loss carryforwards. Despite its significant efforts, the Company has been unable to identify an acceptable transaction that would enable it to implement this utilization strategy."